PT-141 for Women: Enhancing Sexual Desire Safely

Overview

Hypoactive Sexual Desire Disorder (HSDD) affects many women, diminishing their interest in sexual activities and impacting their quality of life. PT-141, marketed as Vyleesi, is a breakthrough treatment approved by the FDA specifically for premenopausal women with HSDD. This injectable medication offers an alternative to oral treatments like Addyi (flibanserin), providing a new option for those seeking to enhance their sexual health.

Mechanism of Action

PT-141, or bremelanotide, works by activating melanocortin receptors in the brain, particularly MC4R and MC3R, which are associated with sexual arousal and desire. Unlike other treatments that rely on hormonal pathways, PT-141 directly influences the central nervous system to increase sexual desire, making it effective for women who may not respond to hormone-based therapies.

Clinical Evidence

PT-141's efficacy was demonstrated in two pivotal clinical trials, RECONNECT 1 and RECONNECT 2, which involved over 1,200 premenopausal women with HSDD. Results showed a significant improvement in the Female Sexual Function Index (FSFI) desire domain scores compared to placebo. Participants also reported higher levels of sexual satisfaction, with minimal adverse effects. These studies underscore PT-141's potential to improve sexual desire and overall sexual experience.

Patient Selection

PT-141 is designed for premenopausal women diagnosed with HSDD who have experienced a decrease in sexual desire that causes distress or interpersonal difficulties. Candidates should have ruled out other potential causes of decreased libido, such as relationship issues or medical conditions. It is important for patients to consult with healthcare providers to determine if PT-141 is the right choice for their specific needs.

MEDVera Protocol

At MEDVera, we offer PT-141 injections as part of our comprehensive sexual health treatments. Our protocol includes an initial consultation to assess suitability, followed by a personalized treatment plan. PT-141 is administered as a subcutaneous injection, typically 45 minutes before anticipated sexual activity, allowing for flexibility and convenience.

FAQ

How does PT-141 differ from Addyi?
While Addyi is an oral medication that affects serotonin levels in the brain, PT-141 is an injectable that acts directly on melanocortin receptors, providing a different mechanism of action.

Is PT-141 safe?
Clinical trials have shown that PT-141 is generally well-tolerated, with the most common side effects being nausea, flushing, and headache.

Can PT-141 be used in postmenopausal women?
Currently, PT-141 is FDA-approved for premenopausal women. Ongoing research is exploring its efficacy in other populations.

How is PT-141 administered?
PT-141 is self-administered via a subcutaneous injection, typically into the abdomen or thigh.

Where can I access PT-141?
MEDVera provides PT-141 treatment in various states, including Texas, Florida, and California. Start your journey with us today.

Ready to explore? Start your free MEDVera evaluation.